The results of two trials comparing TAVR to surgical aortic valve replacement for patients with severe aortic stenosis, but low surgical risk, were released. These results showed a lower rate of death and stroke with TAVR compared to surgery in one trial, and equivalence in the other trial. In addition, patients were rehospitalized less and recovered much more quickly with TAVR.
Today, results of two trials of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement for patients with low surgical risk who have severe aortic stenosis were released. These two trials included almost 2000 patients randomized to either traditional surgical valve replacement or transcatheter valve replacement. The results showed a lower rate of death and stroke with TAVR compared to surgery in one trial, and equivalence in the other trial. In addition, patients were rehospitalized less and recovered much more quickly with TAVR.
Currently, TAVR is approved for patients that are at intermediate and high surgical risk, but TAVR will likely be approved for use in low-risk patients based on this data.
At the Columbia Structural Heart and Valve Center, we are one of the highest volume sites in the country, taking on the most difficult cases as well as more straightforward cases. Our keys to success is an integrated and comprehensive approach to each patient. Our team, composed of cardiologists, surgeons, and imaging experts, are the most experienced team in the country. We are excited to be able to offer TAVR to our patients.
For more information on the TAVR studies, please visit the original articles:
- Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
- Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients